1 A BLUEPRINT FOR BIOBANKING IN EVERYDAY CLINICAL PRACTICE IN PSYCHIATRY: THE 2 MUNICH MENTAL HEALTH BIOBANK

3

4 Authors

5

6 Kalman JL ^{1,2}, Burkhardt G ², Adorjan K ^{1,2}, Barton BB ², De Jonge S ², Eser-Valeri D ², Falter-Wagner CM², Heilbronner U¹, Jobst A², Keeser D^{2,3}, Koenig C², Koller G², Koutsouleris N 7 ^{2,4,5}, Kurz C², Landgraf D², Merz K², Musil R², Nelson AM ^{2,3}, Padberg F², Papiol S^{1,2}, Pogarell 8 O², Perneczky R^{2,6,7,8,9}, Raabe F^{2,10}, Reinhard MA², Richter A², Rüther T², Simon MS², Schmitt 9 A ^{2,11}, Slapakova L ^{2,10}, Scheel N ², Schüle C ², Wagner E ², Wichert SP ², Zill P ²⁺, Falkai P ²⁺, 10 Schulze TG ^{1,12,13}⁺, Schulte EC ^{1,2}⁺ 11 12 13 1 Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, 14 Munich, Germany 15 2 Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, 16 Germany 17 3 NeuroImaging Core Unit Munich (NICUM), University Hospital LMU, Munich, Germany

- 18 4 Max Planck Institute of Psychiatry, Munich, Germany
- 19 5 Institute of Psychiatry, Psychology and Neuroscience, Kings College London, United20 Kingdom
- 21 6 German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany
- 22 7 Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- 23 8 Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College
- 24 London, London, UK
- 25 9 Sheffield Institute for Translational Neurosciences (SITraN), University of Sheffield,
- 26 Sheffield, UK
- 27 10 International Max Planck Research School for Translational Psychiatry, Munich, Germany
- 11 Laboratory of Neuroscience (LIM27), Institute of Psychiatry, University of São Paulo, São
 Paulo, Brazil
- 30 12 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of
- 31 Medicine, Baltimore, MD, USA
- 32 13 Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University,
- 33 Syracuse, NY, USA
- 34
- ⁺ These authors have contributed equally to this work and share last authorship
- 36

37 Corresponding Author:

- 38 Janos L. Kalman, MD
- 39 Institute of Psychiatric Phenomics and Genomics (IPPG),
- 40 University Hospital, LMU Munich,
- 41 Nussbaumstr. 7
- 42 80336 Munich, Germany
- 43 Tel: +49-89-4400-53403
- 44 Email: janos.kalman@med.uni-muenchen.de
- 45 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- Keywords: psychiatry, mental health, biobank, real-world data, broad consent,
 representativeness, electronic health records, medical informatics initiative
- 48

49 Funding

- 50 C.F.W., A.N., and N.S. were supported by the DFG (German Research Council) (grant
- 51 numbers: FA 876/3-1; 876/5-1).
- 52 U.H. was supported by European Union's Horizon 2020 Research and Innovation
- 53 Programme (PSY-PGx, grant agreement No 945151).
- 54 **D.L.** was supported by the Deutsche Forschungsgemeinschaft, Emmy Noether fellowship
- 55 (LA4126/1-1)
- 56 **E.C.S.** was supported by the Munich Clinician Scientist Program.
- 57 58

59 **Conflicts of Interest**

- 60 **R.M.** has received speakers honoraria from Otsuka Pharmaceuticals. He serves or has served
- 61 as PI in clinical trials sponsored by Abide Therapeutics (Lundbeck), Böhringer-Ingelheim,
- 62 Emalex Biosciences, Oryzon, Otsuka Pharmaceuticals.
- 63 F.P. is a member of the European Scientific Advisory Board of Brainsway Inc., Jerusalem,
- 64 Israel, and the International Scientific Advisory Board of Sooma, Helsinki, Finland. He has
- 65 received speaker's honoraria from Mag&More GmbH, the neuroCare Group, Munich,
- 66 Germany, and Brainsway Inc. His lab has received support with equipment from neuroConn
- 67 GmbH, Ilmenau, Germany, Mag&More GmbH and Brainsway Inc.
- 68 69

70 Author contributions

- 71 Concept and design: Kalman, Schulte, Wichert, Zill, Schulze, Falkai
- 72 Analysis and interpretation of data: Kalman, Burkhardt, Schulte
- 73 Drafting of the manuscript: Kalman, Schulte, Burkhardt, Zill, Wichert
- 74 All other authors provided data, contributed ideas and suggestions for analyses, interpreted
- 75 results and revised the final manuscript.
- 76

77 Abstract

Translational research on complex, multifactorial mental health disorders, such as bipolar
disorder, major depressive disorder, schizophrenia, and substance use disorders requires
databases with large-scale, harmonized, and integrated real-world and research data.

81 The Munich Mental Health Biobank (MMHB) is a mental health-specific biobank that was established in 2019 to collect, store, connect, and supply such high-quality phenotypic data 82 83 and biospecimens from patients and study participants, including healthy controls, recruited 84 at the Department of Psychiatry and Psychotherapy and the Institute of Psychiatric 85 Phenomics and Genomics, University Hospital of the Ludwig-Maximilians-University (LMU), 86 Munich, Germany. Participants are asked to complete a questionnaire that assesses 87 sociodemographic and cross-diagnostic clinical information, provide blood samples, and grant access to their existing medical records. The generated data and biosamples are available to 88 89 both academic and industry researchers. In the current manuscript, we outline the workflow 90 and infrastructure of the MMHB, describe the clinical characteristics and representativeness 91 of the sample collected so far, and reveal future plans for expansion and application.

As of October 31, 2021, the MMHB contains a continuously growing set of data from 578 patients and 104 healthy controls (46.37% female; median age, 38.31 years). The five most common mental health diagnoses in the MMHB are recurrent depressive disorder (38.78%; ICD-10: F33), alcohol-related disorders (19.88%; ICD-10: F10), schizophrenia (19.69%; ICD-10: F20), depressive episode (15.94%; ICD-10: F32), and personality disorders (13.78%; ICD-10: F60). Compared with the average patient treated at the recruiting hospitals, MMHB

- 98 participants have significantly more mental health-related contacts, less severe symptoms,
- and a higher level of functioning. The distribution of diagnoses is also markedly different in
- 100 MMHB participants compared with individuals who did not participate in the biobank.
- 101 After establishing the necessary infrastructure and initiating recruitment, the major tasks for
- 102 the next phase of the MMHB project are to improve the pace of participant enrollment,
- 103 diversify the sociodemographic and diagnostic characteristics of the sample, and improve the
- 104 utilization of real-world data generated in routine clinical practice.

106 1. Background

107 In recent years, technological and methodological advances have enabled diseases to be 108 studied at an unprecedented depth and expanse. Biobanks, which collect, store, manage, and 109 share large sets of biosamples and deep phenotyping information, are critical infrastructures 110 for the clinical translation of these advances into patient care.

111 Establishing such rich datasets is especially important for mental health disorders because 112 current diagnostic categories have low prognostic value, disease biomarkers are largely 113 lacking, and novel therapeutic approaches have often failed to reduce the global burden of 114 these disorders (1,2). Nevertheless, mental health disorders are underrepresented in 115 population-based biobanking efforts, and even the largest and most successful biobanks, such as the UK Biobank and the Estonian Biobank, began to collect extensive mental health-related 116 117 phenotypes only years after their initiation (3,4). The reasons for this delay may include the 118 significant resources and commitment required for mental health phenotyping and the 119 difficulties in utilizing real-world data for mental health research because of the lack of data structure, standardization, and interoperability (5). Social stigma attached to many mental 120 121 disorders and the special legal implications, such as legal guardianship, may further reduce 122 the willingness and ability of patients to participate in biobanking efforts.

123 Similar trends are seen in Germany: Currently, only a few, large mental health facilities routinely collect phenotype and biological data, and most of these efforts focus on individuals 124 125 participating in clinical studies and do not include patients in routine clinical practice (6–8). 126 Therefore, to facilitate biobanking in mental health, we established the Munich Mental Health 127 Biobank (MMHB), which intimately entwines the collection of both routine clinical and 128 research phenotyping data and biological specimens at a large tertiary care center in Munich, 129 Germany, comprising the Department of Psychiatry and Psychotherapy (DPP) and the 130 Institute of Psychiatric Phenomics and Genomics (IPPG). In the current manuscript, we 131 describe the workflow and information technology infrastructure of the MMHB, provide a first glimpse into the clinical characteristics of the sample collected so far, analyze the 132 representativeness of the sample with regard to a variety of key clinical and 133 sociodemographic characteristics, and reveal future plans for expansion and application. 134

135

136 2. The MMHB

137 The DPP and IPPG are part of the hospital system of the University Hospital of the Ludwig-138 Maximilians-University (LMU) Munich, Germany. With 3222 unique cases (inpatient: 1058; day hospital: 130; and outpatient: 2034) annually (2020 data), these two institutes are among 139 140 the largest university-based mental health facilities in Germany. Both institutes are 141 internationally renowned strongholds of mental health research and are currently hosting 142 over 43 ongoing clinical studies. However, until recently, neither the DPP nor the IPPG had access to an organized, standardized, high-throughput hospital-wide collection of phenotypes 143 144 and biosamples, markedly limiting large-scale translational research. This changed in 2019 with the establishment of the MMHB. Since then, all individuals treated at the DPP and IPPG, 145 as well as study participants (both patients with a mental health diagnosis and healthy 146 147 controls with no self-reported lifetime mental health diagnosis participating in clinical or non-148 clinical trials), are eligible for inclusion in the MMHB and can be invited to provide informed 149 consent to the collection of phenotypic information and biosamples as part of the biobanking 150 effort.

151 2.1. Informed Consent

152 For the following activities, the MMHB aims to obtain modular informed consent from participants that conforms with the General Data Protection Regulation of the European 153 154 Union: 1) the collection, storage, analysis, scientific utilization, and distribution of deep 155 phenotypic data and biosamples in a double-pseudonymized form to academic and nonacademic research institutions, national and international data archives, and companies, and 156 the linkage of this data to routine clinical data; 2) re-contacting participants to request 157 additional data and biosamples and/or to invite them to participate in new studies; 3) re-158 159 contacting participants to seek consent for linking the collected data to other databases; and 160 4) re-contacting participants to inform them about actionable incidental findings. By providing 161 their consent, MMHB participants allow researchers to use their phenotypic data and 162 biosamples for any type of research, including omics studies and the creation of induced pluripotent stem cell (iPSC) lines, for 30 years. MMHB participants can withdraw their consent 163 164 at any time without providing a specific reason. In case of withdrawal of consent, they can decide whether their data and biosamples should be deleted and destroyed or anonymized. 165

166 2.2. The MMHB phenotyping battery

The MMHB phenotyping battery consists of three components: 1) a basic phenotyping 167 *module*, which builds on previous national multi-centric phenotyping efforts, such as the 168 PsyCourse Study and the PD-CAN study; 2) a module consisting of seven standardized self-169 170 rating measurements with cross-disorder utility; and 3) a variable module that highlights a 171 specific topic of research in more detail and changes every two years (Table 1) (9). In 2020 172 and 2021, the variable module focused on metabolic risk, eating behavior, and stress related 173 to the COVID-19 pandemic. To reduce the biobanking-associated clinician workload, self-174 rather than observer-rating tools are used to obtain patient characteristics and symptom 175 scores. The MMHB phenotyping battery is complemented by data collected in association 176 with specific scientific projects or clinical trials.

Table 1: Overview of the phenotypes assessed with the Munich Mental Health Biobank(MMHB) phenotyping battery

Module	Questionnaire	Reference	
Basic phenotyping	Sociodemographic information		
	Psychiatric medical history		
	Family history		
	Pharmacologic treatment		
	Self-destructive behavior & suicidality		
	Substance abuse, including the Alcohol Use Disorders Identification Test (AUDIT-C)	Bush et al. 1998 (10)	
Standardized self- rating instruments	Childhood Trauma Screener	Grabe et al. 2021 (11)	
	Brief Resilience Scale	Smith et al. 2008 (12)	
	UCLA Loneliness Scale (3-item version)	Hughes et al. 2004 (13)	
	Lubben Social Network Scale	Lubben et al. 2006 (14)	
	WHO-5 Well-Being Index	Topp et al. 2015 (15)	
	Patient Health Questionnaire (PHQ-9)	Kroenke et al. 2001 (16)	
	Munich Chronotype Questionnaire	Roenneberg et al. 2003 (17)	
Variable module (2020/2021)	Questions on metabolic risk	Adapted from Barton et al. 2020 (18)	
	Questions on eating behavior	Adapted from Cappelleri et al. 2009 (19)	
	COVID-19 Pandemic Mental Health Questionnaire (CoPaQ)	Rek et al. 2021 (20)	

180

181 2.3. Biosamples

A limited amount of blood (maximum 70 mL) and, if available, cerebrospinal fluid (maximum
10 mL) is collected from consented individuals during routine clinical examinations or study
visits (Supplementary Table S2). Participants may also be asked to provide saliva, hair, and
stool samples.

186 2.4. Linked routine clinical data

187 Routine clinical data stored in electronic health records or other databases can be linked with
188 the phenotypic information and biosamples collected from MMHB participants and then used
189 for research purposes.

190 2.5. Data and sample processing

191 The collected phenotypic data and biosamples are processed by specially trained staff 192 according to standard operating procedures for data collection, handling, and storage. For each MMHB participant, an electronic record, which includes general and disease-specific 193 194 clinical information, dates of phenotype and biosample acquisitions, and information on 195 sample processing (i.e., identification code, quantity, location of storage, and type of preparation) is captured in CentraXX (Kairos GmbH, Bochum, Germany), a standardized 196 197 laboratory information management system. CentraXX is fully integrated into the laboratory 198 automation infrastructure and, besides the administration of biosamples, enables the 199 acquisition and management of all clinical and phenotypic data of participants. Biosamples 200 (DNA, RNA, serum, plasma, etc.) are processed on site with automated systems 201 (ChemagicStar, Decapper/Barcode Reader, and a StarPlus System; Hamilton Robotics GmbH, Martinsried, Germany) and are stored at -80°C in an automated sample storage and 202 203 management system (BIOS M System, Hamilton Storage GmbH, Bonaduz, Switzerland) (Figure 204 1).

206 Figure 1: Workflow of the Munich Mental Health Biobank

207 Clinical data and biological materials are stored in pseudonymized form in the information 208 management system CentraXX (Kairos GmbH, Bochum, Germany). Biological materials are 209 stored at -80°C, except for peripheral blood mononuclear cells, which are stored in liquid 210 nitrogen (*Supplementary Table S2*). Researchers can request data access by completing a 211 request form. If the Data Access Committee approves the request, a material and/or data

transfer agreement is signed, and the data and biological materials can be provided.

213 Abbreviations: CSF, cerebrospinal fluid; EHR, electronic health record; PBMCs, peripheral

- 214 blood mononuclear cells
- 215



217 2.6. Data availability

The collected phenotypes and biomaterials are available to both academic and industry 218 researchers upon request. The process for requesting data and biomaterials is as follows: 1) 219 220 Requestors send an email with a description of the planned scientific project, the type and 221 quantity of the requested data, and their data protection policies to the MMHB (psy mmhb@med.uni-muenchen.de) to inquire about data availability, and in the same 222 223 email, they may also propose collaborations with local researchers; 2) the Data Access Committee evaluates the feasibility of the project and provides a cost estimate for sample 224 225 extraction, processing, and shipment; 3) at this point, requestors provide documentation 226 confirming ethical approval of the proposed project; 4) the MMHB provides a quote, data-227 and material transfer agreements (DTA and MTA, respectively); and 5) once the DTA and/or 228 MTA is signed by both parties, the biological materials and double-pseudonymized 229 phenotypic and omics data are sent to the requestor. Depending on the legal process, approximately four to six months should be allowed from submission of the project proposal 230 to delivery of the data and/or biomaterials. 231

232 3. Sample characteristics

Detailed phenotype definitions of the MMHB Sample and Clinical Sample (i.e., the target 233 234 population of all patients treated at the DPP and IPPG during the same period who were 235 eligible for inclusion in the MMHB but were not included) are provided in the description of 236 the individual analyses and in Supplementary Table S1. Qualitative traits were analyzed with 237 non-parametric pairwise Mann-Whitney U tests, and quantitative traits, with $\chi 2$ tests. The 238 significance threshold was set at 0.05. The study protocol was approved by the local ethics 239 committee, and the study was performed in accordance with the Declaration of Helsinki. All 240 participants in the MMHB Sample provided written informed consent. The Clinical Sample 241 served as naturalistic comparator: the data was generated in the clinical routine and 242 irreversibly anonymized for further analysis.

243 3.1. The MMHB Sample

Recruitment for the MMHB started on April 11, 2019. As of October 31, 2021, 578 patients 244 and 104 healthy controls had been included in the MMHB. Table 2 and Figure 2 provide an 245 246 overview of the demographic and clinical characteristics of the sample. Participants were 247 more likely to be recruited in an inpatient setting (67.47%) than in the day hospital (3.46%) or 248 outpatient clinic (29.07%). The analysis included all (independent) clinical (ICD-10) diagnoses 249 the patient received during the observational period (April 11, 2019, to October 31, 2021). The most frequent ICD-10 diagnoses were recurrent depressive disorder (38.78%; ICD-10: 250 251 F33), alcohol-related disorders (19.88%; ICD-10: F10), schizophrenia (19.69%; ICD-10: F20), 252 depressive episode (15.94%; ICD-10: F32), and personality disorders (13.78%; ICD-10: F60). A 253 full list of the diagnoses and the respective frequencies is provided in Supplementary Table 254 S3.

255 3.2. Comparison of the MMHB Sample and the Clinical Sample

Next, we compared the basic sociodemographic and clinical characteristics of the MMHB Sample with the Clinical Sample (i.e., the target population of all patients treated at the DPP and IPPG during the same period who were eligible for inclusion in the MMHB but were not included). The two samples had similar age and sex distributions (*Table 2*). Clinicians at the DPP and IPPG routinely assess the seven-day functioning and disease severity of inpatients

and day hospital patients at admission and discharge by using the Global Assessment of 261 262 Functioning (GAF) and Clinical Global Impression (CGI) scales, respectively (21,22). According 263 to these measures, patients in both the MMHB and Clinical samples had severe symptoms 264 and major impairments in functioning at admission and moderate symptoms and improved functioning at discharge. However, compared with the Clinical Sample, MMHB participants 265 266 who had been recruited as inpatients had significantly higher functioning at both admission (GAF-A_{MMHB}= 40 vs. GAF-A_{Clinical Sample}= 35, Mann-Whitney-U-Test, $p = 8.10 \times 10^{-15}$) and 267 discharge (GAF-D_{MMHB}= 55 vs. GAF-D_{Full Clinical Sample} = 55, $p = 5.18 \times 10^{-3}$) and less severe 268 symptoms at admission (CGI-A_{MMHB}= 5 vs. CGI-A_{Clinical Sample}= 5, $p = 3.77 \times 10^{-5}$). Symptom 269 severity at discharge (CGI-D) was similar in both groups. No significant differences were 270 observed between the MMHB and Clinical samples of day hospital patients. GAF and CGI 271 272 values were not available for the outpatients. During the observation period, patients in the MMHB Sample were hospitalized more frequently than those in the Clinical Sample (number 273 of hospitalizations: 2 vs. 1; Mann-Whitney U test, $p = 8.04 \times 10^{-41}$), for longer periods of time 274 (total length of stay, 71 vs. 37 days; $p = 2.94 \times 10^{-37}$), and had more outpatient contacts (6 vs. 275 1; $p = 4.35 \times 10^{-30}$) (Table 2). 276

277 Figure 2 provides an overview of the prevalence in the two samples of the 15 most frequent 278 diagnoses derived from the Clinical Sample. In the MMHB Sample vs the Clinical Sample, we 279 observed the most pronounced differences in the prevalence of recurrent depressive disorder 280 (38.78% vs 32.12%; ICD-10: F33), adjustment disorder (9.65% vs 15.17%; ICD-10: F43), 281 alcohol-related disorders (19.88% vs 11.44%; ICD-10: F10), schizophrenia (19.69% vs 9.64%; 282 ICD-10: F20), personality disorders (13.78% vs 7.72%; ICD-10: F60), and schizoaffective 283 disorder (8.27% vs 3.32%; ICD-10: F25). A full list of diagnoses and the respective frequencies 284 is provided in *Supplementary Table S3*.

285

287 Table 2. Sample characteristics

Variable	Group	MMHB Sample	Clinical Sample	р
N , (%) ^a	Healthy controls	104		
	Inpatients	390 (67.47%)	2274 (22.93%)	
	Day hospital	20 (3.46%)	383 (3.86%)	
	patients			
	Outpatients	168 (29.07%)	7252 (73.20%)	
Age, median (MAD; range) ^b	Healthy controls	32.42 (11.76; 19.62-64.97)		
	Patients	38.31 (18.30; 18.08-93.07)	39.00 (19.27; 4-98)	0.39
Sex, % male	Healthy controls	53.85		
	Patients	53.63	52.07	0.50
GAF-A , median (MAD; range) ^{b,c}	Inpatients	40.0 (7.41; 7-65)	35 (7.41; 0-75)	8.10×10 ⁻¹⁵
	Day hospital patients	46 (6.67; 30-61)	45 (7.41; 25-65)	0.89
GAF-D , median (MAD; range) ^{b,c}	Inpatients	55 (7.41; 21-90)	55 (10.38; 0-95)	5.18×10 ⁻³
	Day hospital	60 (7.41; 31-70)	55 (7.41; 25-80)	0.06
CGLA median (MAD: range) ^{b,c}	Innationts	5 (0.3-7)	5 (0: 2-7)	3 77×10-5
CorA, median (MAD, range)	Day hospital	5 (1.48; 3-6)	4 (0; 3-6)	0.23
CGI-D, median (MAD; range) ^{b,c}		4 (0, 2, 6)	4 (0, 1, 7)	0.72
	Day bosnital	4 (0, 2-6)	4(0, 1-7)	0.75
	patients	4 (0, 5-0)	5 (0, 2-0)	0.50
Days hospitalized, median (MAD; range) ^{b,d}		71 (62.27; 1-502)	34 (34.10; 1-585)	2.94×10 ⁻³⁷
Number of hospitalizations, median (MAD; range) ^{b,d}		2 (1.48; 1-49)	1 (0; 1-62)	8.04×10 ⁻⁴¹

Number of outpatient visits,	6 (7.41; 1-165)	1 (0; 1-279)	4.35×10 ⁻³⁰
median (MAD; range) ^{b,d}			

Abbreviations: CGI-A & CGI-D, Clinical Global Impression at admission & discharge, respectively; GAF-A & GAF-D, Global Assessment of Functioning at admission & discharge, respectively; MAD, median absolute deviation; MMHB, Munich Mental Health Biobank; p, unadjusted p value (significant p values are indicated in bold).

291 *Note:* See *Supplementary Material* for detailed phenotype descriptions. ^a Proportion of inpatients, day hospital patients, and outpatients among

all patients (N = 578). ^b The MAD was calculated by using 1.4826 as a constant. ^c GAF and CGI values were available only for a subset of inpatients

293 (N_{MMHB}=376, N_{Clinical Sample}= 2117) and day hospital (N_{MMHB}=11, N_{Clinical Sample}= 254) patients. ^d Days hospitalized (as either an inpatient or a day

hospital patient) and the number of outpatient visits between April 11, 2019, and October 31, 2021, to the Department of Psychiatry and

295 Psychotherapy or Institute of Psychiatric Phenomics and Genomics. Patients with no hospitalizations and/or outpatient contacts were excluded

from the respective analyses.

298

Figure 2: Differences in diagnosis frequency between the Munich Mental Health Biobank(MMHB) and Clinical samples

301 Comparison of the prevalence of the 15 most frequent diagnoses derived from the Clinical

302 Sample in the Munich Mental Health Biobank and the Clinical Sample. The diagnoses were

303 defined as all (independent) clinical (ICD-10) diagnoses the patient received during the

observational period (April 11, 2019, to October 31, 2021). A full list of diagnoses and their

305 respective frequencies is provided in *Supplementary Table S3*.



306

Abbreviations: F33, recurrent depressive disorder; F32, depressive episode; F43, adjustment 307 308 disorder; F10, alcohol-related disorders; F20, schizophrenia; F60, personality disorders; F31, 309 bipolar disorder; F41, other anxiety disorders; F12, mental and behavioural disorders due to 310 use of cannabinoids; F13, mental and behavioural disorders due to use of sedatives or 311 hypnotics; F25, schizoaffective disorder; F17, mental and behavioural disorders due to use of 312 tobacco; F11, mental and behavioural disorders due to use of opioids; F19, mental and 313 behavioural disorders due to multiple drug use and use of other psychoactive substances; 314 F42, obsessive-compulsive disorder; MMHB, Munich Mental Health Biobank

315



Figure 3: Growth of the Munich Mental Health Biobank (MMHB) and Clinical samples over time

320 Abbreviation: MMHB, Munich Mental Health Biobank

321 4. Discussion

322 The MMHB is a mental health-specific biobank that aims to integrate multimodal research and real-world phenotypic information with biosamples of patients with mental health 323 324 disorders and study participants, including healthy controls, to facilitate translatable mental 325 health research and, ultimately, improve patient care. Here, we outlined the information 326 technology and laboratory infrastructure and the administrative processes of the MMHB, 327 described the clinical and sociodemographic characteristics of the 578 patients and 104 328 healthy controls included in the MMHB so far and compared this sample with the overall 329 target population treated at the recruitment facilities. This initial evaluation allows us to 330 discuss the representativeness and scope of the MMHB sample, identify limitations of our 331 current recruitment strategy, and derive action points that could further improve the quality 332 of the MMHB data.

333 4.1. Representativeness

334 There is increasing evidence that individuals with certain non-random characteristics, such as 335 lower socioeconomic and education status, poorer health, non-European ancestry, and 336 increased cumulative genetic burden for schizophrenia, neuroticism, and attention-deficit 337 hyperactivity disorder, are less likely to participate in clinical studies and more likely to drop out during the follow-up period (9,23-25). These data are concerning because non-338 339 participation and attrition not only are associated with a loss of statistical power, but, if non-340 random, can also influence sample representativeness and thereby bias the generalizability 341 and real-life utility of research findings, health policy decision-making, and ultimately, the 342 equity of health care provision (26). Compared with patients treated at the DPP and IPPG 343 since April 11, 2019 who were not included in the MMHB (Clinical Sample), we found that 344 certain mental health diagnoses, such as schizophrenia, schizoaffective disorder, alcohol-345 related disorders, and personality disorders, are overrepresented in the MMHB sample, 346 whereas adjustment disorders, for example, are relatively underrepresented, most likely 347 because recruitment so far has been propagated by study teams interested in answering specific research questions. Interestingly, we found evidence that the frequency and length 348 349 of contact with the health care system differed between the target population (i.e., those not 350 included in the biobank) and the MMHB sample: MMHB participants were not only more 351 frequently hospitalized (median number of hospitalizations in MMHB Sample vs Clinical 352 Sample, 2 vs 1), but they also spent more days in hospital (median, 71 vs 37 days) and had 353 more outpatient appointments (6 vs 1) during the 30-month observational period. The 354 proportion of participants recruited in an inpatient setting was also higher in the MMHB Sample than in the Clinical Sample (67.47% vs 22.93%). These differences could be explained 355 356 by potential systematic sampling biases in that study personnel and clinicians are more likely to ask "known" patients to consent to being included in the MMHB and/or that patients with 357 358 repeated contacts with the same institution are more likely to trust that institution and 359 participate in its research efforts. Also, longer hospitalizations and more frequent visits in 360 general represent more opportunities to recruit participants. These observations emphasize 361 the importance of interpersonal factors (such as trust, rapport, and compliance) and the type 362 and frequency of contact with the health care system in study participation. These factors are 363 potential sources of recruitment bias that should be taken into consideration when analyzing 364 the MMHB Sample. Interestingly, despite the more frequent health care utilization, the 365 MMHB Sample had less severe symptoms and higher levels of functioning (measured with 366 CGI and GAF, respectively) at inclusion in the biobank than the Clinical Sample in general.

Although this difference is likely not clinically meaningful (the difference in functioning was
 within a 10-point GAF range), it still suggests that patients who were successfully recruited
 had better overall social, occupational, and psychological functioning.

370 4.2. Availability of real-world clinical data

371 As outlined, the current MMHB phenotyping battery includes detailed sociodemographic and 372 self-reported transdiagnostic information that enables research across multiple disorders and 373 patient subgroups. However, like most other mental health-specific biobanks, currently the 374 MMHB includes only a limited set of features from routine clinical care (patient age, sex, zip 375 code, GAF, CGI, diagnosis, and laboratory results). This limited information is a direct result of 376 the limitations of current electronic health record systems, which are markedly restricted in 377 their ability to present relevant mental health information in a standardized, structured, 378 interoperable, and thus machine-readable format. Therefore, our current data mainly include 379 only cross-sectional information and lack real-world clinical data and longitudinal information 380 on disease trajectories. These data modalities, however, represent a main target of current 381 data-driven precision medicine initiatives, which aim at developing reliable, generalizable 382 prediction models of important mental health-related outcomes, such as antidepressant 383 response, suicide attempts, and the transition from clinical high-risk states to psychosis (27-384 29).

385 4.3. Outlook

386 A key strength of the MMHB is its close integration into the clinical and scientific 387 infrastructure of a large mental health care center, which not only ensures the necessary 388 domain knowledge for collecting high-quality mental health-specific phenotypes, but also 389 provides direct access to the more than 3000 individual patients treated annually at the DPP 390 and IPPG and thus a strong growth potential (Figure 3). Moreover, this target population has 391 good sociodemographic representativeness because Germany has universal health insurance, 392 ensuring that treatment is offered to all individuals in need. A further asset of the MMHB is 393 the wide age range of eligible participants and the diversity of diagnoses, which enables the 394 study of all stages of the disease trajectory across the whole lifespan and diagnostic spectrum.

Limitations of the MMHB include the observed differences between the MMHB and Clinical samples, the current sparsity of available real-world data, and the moderate recruitment pace (only 5.56% of the 10,494 patients who were treated at the DPP and IPPG during the 30month observational period and were thus eligible for inclusion were recruited into the MMHB, *Figure 3*).

400 To address these limitations, in the next phase of our biobanking effort, we will move from active, interest-driven biobank recruitment towards a more passive, automatized 401 402 participatory system. To achieve this, we will first introduce the Broad Consent of the German 403 Medical Informatics Initiative, for which we have developed an additional Psychiatry Module 404 tailored to the needs of mental health research (30). This modified Broad Consent, which will 405 be valid for 5 years, will enable the scientific use of prospectively collected routine clinical and 406 insurance data, and, via the Psychiatry Module, additionally collected mental health-specific 407 phenotypes, magnetic resonance imaging, electroencephalogram data, and biosamples. 408 Next, we will introduce the Clinical Phenotyping Platform (CliPP), a software solution that 409 enables the collection of structured and standardized (Fast Healthcare Interoperability 410 Resource (FHIR) format) routine mental health data directly from patients and health care 411 providers. Owing to the Broad Consent and the CliPP, the consent process and the phenotypic 412 assessments will be incorporated into routine admission procedures. Their introduction will 413 broaden the available data modalities, reduce the time spent on patient recruitment, and 414 decrease the risk of sampling bias due to physician and/or patient preferences. Furthermore, 415 we will continuously monitor the representativeness of the MMHB Sample, analyze the 416 factors that influence biobank participation, and, if necessary, revise study design and 417 recruitment strategies. Through these measures, we will facilitate recruitment of participants 418 into the MMHB, improve clinician and patient commitment and the representativeness of our 419 sample, and ultimately, increase the scientific and clinical value of the MMHB Sample. Large 420 future transdiagnostic cohorts from the MMHB will leverage forward and reverse 421 translational research in an informative framework spanning preclinical models via disorder 422 focused clinical trials to real-world applications in a transdiagnostic spectrum of mental health 423 disorders including their developmental dynamics and co-morbidities.

424

426 5. References

- Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression
 from 1990 to 2017: Findings from the Global Burden of Disease study. J Psychiatr Res.
 2020 Jul 1;126:134–40.
- John A, McGregor J, Fone D, Dunstan F, Cornish R, Lyons RA, et al. Case-finding for
 common mental disorders of anxiety and depression in primary care: an external
 validation of routinely collected data. BMC Med Inform Decis Mak. 2016 Mar 15;16:35.
- 433 3. Biobanking.com. Large Study on Mental Health Genetics Launched by Estonian Biobank 434 [Internet]. Biobanking.com. 2021 [cited 2022 Apr 12]. Available from: 435 https://www.biobanking.com/large-study-on-mental-health-genetics-launched-by-436 estonian-biobank/
- 437 4. Davis K, Hotopf M. Mental health phenotyping in UK Biobank. Prog Neurol Psychiatry.
 438 2019;23(1):4–7.
- 439 5. Gehring S, Eulenfeld R. German Medical Informatics Initiative: Unlocking Data for
 440 Research and Health Care. Methods Inf Med. 2018 Jul;57(Suppl 1):e46–9.
- Witt S, Dukal H, Hohmeyer C, Radosavljevic-Bjelic S, Schendel D, Frank J, et al. Biobank
 of Psychiatric Diseases Mannheim BioPsy. Open J Bioresour. 2016 Jul 8;3(1):e2.
- Klingler C, von Jagwitz-Biegnitz M, Hartung ML, Hummel M, Specht C. Evaluating the
 German Biobank Node as Coordinating Institution of the German Biobank Alliance:
 Engaging with Stakeholders via Survey Research. Biopreservation Biobanking. 2020
 Apr;18(2):64–72.
- 447 8. Hummel M, Specht C. Biobanks for future medicine. J Lab Med. 2019 Dec 1;43(6):383–
 448 8.
- Budde M, Anderson-Schmidt H, Gade K, Reich-Erkelenz D, Adorjan K, Kalman JL, et al. A
 longitudinal approach to biological psychiatric research: The PsyCourse study. Am J Med
 Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet. 2019
 Mar;180(2):89–102.
- Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med. 1998 Sep 14;158(16):1789–95.
- 457 11. Grabe HJ, Schulz A, Schmidt CO, Appel K, Driessen M, Wingenfeld K, et al. [A brief
 458 instrument for the assessment of childhood abuse and neglect: the childhood trauma
 459 screener (CTS)]. Psychiatr Prax. 2012 Apr;39(3):109–15.
- 460 12. Smith BW, Dalen J, Wiggins K, Tooley E, Christopher P, Bernard J. The brief resilience
 461 scale: assessing the ability to bounce back. Int J Behav Med. 2008;15(3):194–200.

- Hughes ME, Waite LJ, Hawkley LC, Cacioppo JT. A Short Scale for Measuring Loneliness
 in Large Surveys: Results From Two Population-Based Studies. Res Aging.
 2004;26(6):655–72.
- Lubben J, Blozik E, Gillmann G, Iliffe S, von Renteln Kruse W, Beck JC, et al. Performance
 of an abbreviated version of the Lubben Social Network Scale among three European
 community-dwelling older adult populations. The Gerontologist. 2006 Aug;46(4):503–
 13.
- Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 Well-Being Index: a
 systematic review of the literature. Psychother Psychosom. 2015;84(3):167–76.
- 471 16. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
 472 measure. J Gen Intern Med. 2001 Sep;16(9):606–13.
- 473 17. Roenneberg T, Wirz-Justice A, Merrow M. Life between clocks: daily temporal patterns
 474 of human chronotypes. J Biol Rhythms. 2003 Feb;18(1):80–90.
- Barton BB, Zagler A, Engl K, Rihs L, Musil R. Prevalence of obesity, metabolic syndrome,
 diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of
 the Metabolism in Psychiatry (MiP) Study. Eur Arch Psychiatry Clin Neurosci. 2020
 Aug;270(5):597–609.
- 479 19. Cappelleri JC, Bushmakin AG, Gerber RA, Leidy NK, Sexton CC, Lowe MR, et al.
 480 Psychometric analysis of the Three-Factor Eating Questionnaire-R21: results from a large
 481 diverse sample of obese and non-obese participants. Int J Obes 2005. 2009
 482 Jun;33(6):611–20.
- 20. Rek SV, Bühner M, Reinhard MA, Freeman D, Keeser D, Adorjan K, et al. The COVID-19
 Pandemic Mental Health Questionnaire (CoPaQ): psychometric evaluation and
 compliance with countermeasures in psychiatric inpatients and non-clinical individuals.
 BMC Psychiatry. 2021 Aug 31;21(1):426.
- 487 21. Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health,
 488 Education, and Welfare, Public Health Service ...; 1976.
- 489 22. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale490 reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry J
 491 Ment Sci. 1995 May;166(5):654–9.
- 492 23. Pirastu N, Cordioli M, Nandakumar P, Mignogna G, Abdellaoui A, Hollis B, et al. Genetic
 493 analyses identify widespread sex-differential participation bias. Nat Genet. 2021 May
 494 1;53(5):663–71.
- 495 24. Taylor AE, Jones HJ, Sallis H, Euesden J, Stergiakouli E, Davies NM, et al. Exploring the
 496 association of genetic factors with participation in the Avon Longitudinal Study of
 497 Parents and Children. Int J Epidemiol. 2018 Aug 1;47(4):1207–16.

- Tyrrell J, Zheng J, Beaumont R, Hinton K, Richardson TG, Wood AR, et al. Genetic
 predictors of participation in optional components of UK Biobank. Nat Commun. 2021
 Feb 9;12(1):886.
- 26. Larsson H. The importance of selection bias in prospective birth cohort studies. JCPP Adv.
 2021;1(3):e12043.
- Koutsouleris N, Dwyer DB, Degenhardt F, Maj C, Urquijo-Castro MF, Sanfelici R, et al.
 Multimodal Machine Learning Workflows for Prediction of Psychosis in Patients With
 Clinical High-Risk Syndromes and Recent-Onset Depression. JAMA Psychiatry. 2021 Feb
 1;78(2):195–209.
- Barak-Corren Y, Castro VM, Nock MK, Mandl KD, Madsen EM, Seiger A, et al. Validation
 of an Electronic Health Record-Based Suicide Risk Prediction Modeling Approach Across
 Multiple Health Care Systems. JAMA Netw Open. 2020 Mar 2;3(3):e201262.
- 29. Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, et al. Crosstrial prediction of treatment outcome in depression: a machine learning approach.
 Lancet Psychiatry. 2016 Mar;3(3):243–50.
- Semler SC, Wissing F, Heyder R. German Medical Informatics Initiative. Methods Inf Med.
 2018 Jul;57(Suppl 1):e50–6.